Halozyme Therapeutics Inc (HALO)
Operating return on assets (Operating ROA)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | 337,574 | 311,048 | 306,061 | 245,663 | 267,531 | 249,556 | 241,850 | 300,837 | 275,902 | 296,992 | 261,705 | 198,213 | 144,255 | 34,569 | -30,267 | -73,799 | -67,610 | -35,619 | -36,556 | -42,652 |
| Total assets | US$ in thousands | 1,733,270 | 1,892,660 | 1,810,440 | 1,699,450 | 1,841,510 | 1,864,540 | 1,781,390 | 1,162,250 | 1,104,430 | 1,185,420 | 1,025,860 | 966,582 | 579,924 | 524,029 | 526,997 | 492,353 | 565,874 | 370,356 | 417,830 | 429,109 |
| Operating ROA | 19.48% | 16.43% | 16.91% | 14.46% | 14.53% | 13.38% | 13.58% | 25.88% | 24.98% | 25.05% | 25.51% | 20.51% | 24.87% | 6.60% | -5.74% | -14.99% | -11.95% | -9.62% | -8.75% | -9.94% |
December 31, 2023 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $337,574K ÷ $1,733,270K
= 19.48%
To analyze Halozyme Therapeutics Inc.'s operating return on assets (operating ROA) based on the provided data, we can see fluctuations in the metric over the past eight quarters. Operating ROA indicates the company's efficiency in generating operating income relative to its total assets.
- In Q1 2022, the operating ROA was at a high of 25.88%, reflecting strong operational performance and efficient asset utilization.
- Throughout Q2 and Q3 2022, the operating ROA remained relatively stable in the range of 13.58% to 13.38%.
- In Q4 2022, there was a notable increase to 14.53%, which continued into Q1 2023 at 14.46%. These figures suggest a slight improvement in operational efficiency.
- A significant rise in operating ROA is observed in Q2 2023 to 16.91%, indicating a more robust performance compared to the previous quarters.
- This trend continued into Q3 2023, with a further increase to 16.43%, demonstrating sustained operational effectiveness.
- Q4 2023 witnessed the highest operating ROA during the analyzed period at 19.48%, implying continued improvements in operational income generation relative to assets.
In conclusion, the fluctuating but generally increasing trend in operating ROA for Halozyme Therapeutics Inc. over the past eight quarters suggests improving operational performance and efficiency in utilizing assets to generate operating income.
Peer comparison
Dec 31, 2023